| |
David L. Bellitt joins Bioreliance
David L. Bellitt has been named Vice President of Global Commercial Operations, Biologics. Mr. Bellitt will be responsible for all global commercialization activities, including sales, marketing and customer service. He will also serve as a member of the Corporate Operating Committee.
Click here to read the
press release.
James Kramer joins Bioreliance
James J. Kramer, Ph.D, joins BioReliance as Vice President of
Operations, U.S. Biologics. In his new position, Dr. Kramer is the US
Biologic Services Value Stream leader for the company and has direct
ownership for Program Management, Quality, GMP-Cell Banking, Clearance
Services, Molecular Biology, Cell Biology Microbiology, Virology,
In-Vivo Studies, Support Services and Facilities.
Click here to read the
press release.
David A. Dodd to Lead BioReliance Corporation
David A. Dodd has joined BioReliance as the Company's President, Chief
Executive Officer and Chairman of the Board, effective December 3, 2007.
From 2000 through 2006, Mr. Dodd served as President and CEO of
Serologicals Corporation, a publicly traded company that was sold to
Millipore Corporation in 2006 for $1.4 billion. Prior to that, from
1995 Mr. Dodd was President and CEO of Solvay Pharmaceuticals, Inc.
Click here to read the press release.
|
|
|
|
|
BioReliance provides testing and manufacturing services
that span the product cycle from early pre-clinical development through
licensed production.
|
Our goal is to advance the development and delivery of healthcare products through testing,
development and manufacturing services in partnership with clients worldwide.
Founded in 1947 as Microbiological Associates, BioReliance
is the largest provider of outsourcing services focused on the rapidly
growing biologics sector of the pharmaceutical industry. BioReliance has
provided services to over 600 clients annually, including most of the
largest pharmaceutical and biopharmaceutical companies in the world. For
established biotechnology and pharmaceutical companies, outsourcing to
BioReliance streamlines product development and reduces time to market.
The Company also supports early stage companies who may lack the staff,
expertise and financial resources to conduct many aspects of product development
in-house. BioReliance's services and broad experience provide all of its
clients with a cost-effective alternative to the fixed costs associated
with internal biologics development and manufacture.
All of our studies are conducted in total confidence
and we comply with the latest recommendations from the FDA, ICH, CPMP,
and Japanese Ministry of Health and Welfare. All assays are performed
under full compliance with Good Laboratory Practice (GLP) and Good Manufacturing
Practice (GMP) standards.
We have formed strong partnerships with many of the
world’s leading biopharmaceutical and biotechnology firms; many biologicals
now licensed by the FDA, EMEA and other international agencies have been
tested and validated by BioReliance.
|  |
|
|
